Relmada Highlights NDV-01 Phase 2 Data, Phase 3 Plans
Relmada Therapeutics announced strong 12-month Phase 2 data for NDV-01 in bladder cancer, with complete response rates up to 95% and durable responses up to 80% at 12 months. The company plans to launch its Phase 3 RESCUE program in mid-2026 and has secured $234 million in funding, ensuring operations through 2029 despite increased quarterly net losses. An analyst has rated RLMD stock as a Buy with a $19.00 price target.
How this was made
The 30-second read
Why it matters
The positive clinical data and upcoming Phase 3 trial launch are likely to serve as catalysts for stock appreciation.
Market read
High relevance within biotech and oncology sectors, with potential influence on related stocks and indices.
What to watch
Market sentiment may be overly optimistic; potential regulatory hurdles or funding issues could impact stock performance.
Background
Relmada Therapeutics is advancing its NDV-01 candidate for bladder cancer, with recent positive Phase 2 data and substantial funding secured.
Ticker impact
Recent positive clinical data and funding news suggest potential upside.
Moderate to significant upward movement within 1-3 months, contingent on clinical trial progress and market reception.
Strong clinical data, secured funding, and positive analyst outlook underpin the bullish prediction. The upcoming Phase 3 trial launch is a key catalyst.
Market effects
Positive impact on biotech and pharmaceutical sectors, especially companies involved in oncology and clinical trials.
Primarily US-focused, with potential influence on biotech indices.
Moderate; biotech sector is globally interconnected, but specific to US developments.
Counterpoint
Clinical trial results are preliminary; negative or delayed outcomes could lead to significant declines.
Key entities
- CompanyRelmada Therapeutics
Biotech company focused on developing novel therapies for CNS and oncology indications.
- Drug CandidateNDV-01
Therapeutic candidate showing promising results in bladder cancer.
